Abstract
Thirty patients with advanced gastric carcinoma were treated with doxorubicin combined with mitomycin; only four (13%) responded. Myelosuppression was the major toxic effect; there was one toxic death. The overall median survival was 14 weeks (range, 2-42), which is no different from that reported for untreated patients. The combination of doxorubicin and mitomycin alone cannot be recommended for use in patients with advanced gastric carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 897-898 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 70 |
| Issue number | 7 |
| State | Published - Jan 1 1986 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Treatment of advanced gastric carcinoma with mitomycin and doxorubicin'. Together they form a unique fingerprint.
Cite this
Dalley, D., Erlichman, C., & Fine, S. (1986). Treatment of advanced gastric carcinoma with mitomycin and doxorubicin. Cancer Treatment Reports, 70(7), 897-898.